Related Experiment Video
Updated: Jun 3, 2026
14:37
Directed Differentiation of Primitive and Definitive Hematopoietic Progenitors from Human Pluripotent Stem Cells
Published on: November 1, 2017
Embryonic stem cell-derived hematopoietic stem cells: challenges in development, differentiation, and immunogenicity.
1Quantitative and Systems Biology Graduate Program, School of Natural Sciences, 5200 North Lake Road, Merced, CA 95343, USA.
Current Topics in Medicinal Chemistry
|March 31, 2011
Summary
Embryonic stem cells offer therapeutic potential but face challenges like immune rejection. Inducing mixed hematopoietic chimerism may promote tolerance for ESC-derived therapies.
Area of Science:
- Regenerative Medicine
- Immunology
- Stem Cell Biology
Background:
- Embryonic stem cells (ESCs) possess pluripotency, enabling differentiation into various cell types for therapeutic applications.
- ESC-derived tissues hold promise for treating degenerative diseases and organ damage.
- Significant challenges hinder clinical translation, including inefficient tissue production, poor integration, and immune rejection.
Purpose of the Study:
- To review challenges in developing transplantable ESC-derived hematopoietic stem cells.
- To discuss the in vivo differentiation fate of ESC-derived hematopoietic progenitors.
- To suggest methods for predicting and preventing immunogenicity of ESC-derived hematopoietic cells.
Main Methods:
- Review of existing literature on ESC differentiation and transplantation.
- Analysis of mechanisms underlying immune tolerance induction via hematopoietic chimerism.
- Discussion of strategies for assessing immunogenicity of ESC-derived cells.
Main Results:
- ESC differentiation can yield hematopoietic progenitors, but challenges remain for generating bona fide hematopoietic stem cells.
- Mixed hematopoietic chimerism in mouse models demonstrates potential for inducing tolerance to allogeneic ESC-derived tissues.
- Predictive assays for immunogenicity could guide the selection of ESC-derived hematopoietic populations for transplantation.
Conclusions:
- Overcoming challenges in ESC differentiation and immunogenicity is crucial for realizing therapeutic potential.
- Mixed hematopoietic chimerism offers a promising strategy for immune tolerance in ESC-based therapies.
- Developing methods to predict and mitigate immune rejection is essential for successful clinical application of ESC-derived therapies.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:19Multipotency of Hematopoietic Stem Cells
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
00:57Embryonic Stem Cells
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
00:58Embryonic Stem Cells
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
01:17Stem Cell Culture
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
01:21Hematopoiesis
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...